LEO Pharma to expand in Russian market

4 June 2009

LEO Pharma and Nycomed conclude new marketing agreement in Russia.

The Danish pharmaceutical company LEO Pharma, which today markets drugs in more than 90 countries, has ambitions for further expansion.

In the coming years, LEO Pharma’s existing product portfolio will be extended to include new markets. Most recently, LEO Pharma has established an affiliate in China and a sales force in Mexico. LEO Pharma is now investing in additional marketing in Russia through a new agreement with its partner, Nycomed.
The goal is to increase both sales and earnings.

The agreement with Nycomed, the market leader in Russia with more than 700 employees, means that a 34-strong Nycomed sales team will exclusively market LEO drugs in 13 selected Russian cities with a least one million inhabitants.
The agreement became effective on 1 June 2009 and concerns the marketing of LEO Pharma’s dermatological drugs for the treatment of the chronic skin disease psoriasis (Daivobet®), eczema and other skin infections (the Fucidin® products).

"We have worked closely with Nycomed in the Russian market since 2005 and generated good results. But while we are extremely satisfied with our results, we believe that we can do even better, and that is the background for our expansion plans international", says Lars Minor, Director in LEO Pharma International, referring to an annual growth rate of 50% for LEO Pharma in Russia in the past few years.

Nycomed is a privately-owned global pharmaceutical company, and the company will be responsible for the LEO Group’s marketing, logistics and distribution activities in Russia.
Nycomed is represented in more than 50 countries and the group’s products are sold in more than 100 countries. Nycomed has 12,000 employees and its revenue totalled EUR 3.4 billion in 2008.

About LEO Pharma
LEO Pharma is an independent, research-based pharmaceutical company based in Ballerup near Copenhagen. LEO Pharma is wholly owned by the LEO Foundation and is one of the world’s leading companies within dermatology (skin diseases) and the parenteral treatment of thromboembolisms (thrombosis).
LEO Pharma discovers, develops, manufactures and markets safe and efficacious drugs globally. 96% of LEO Pharma’s turnover (5.7 billion DKK in 2008) stems from outside Denmark. LEO Pharma is represented in more than 90 countries and has approx. 3,000 employees, of whom 1,200 work in Denmark.

For more information, please contact:

LEO Pharma
Corporate Communications
Tel.: +45 4494 5888

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.